BioCentury
ARTICLE | Clinical News

RG1577: Completed Phase IIb enrollment

June 2, 2014 7:00 AM UTC

Evotec disclosed in its 1Q14 earnings that Roche completed enrollment of the placebo-controlled, international Phase IIb MAyflOwer RoAD trial to evaluate 2 doses of oral RG1577 for 52 weeks in about 4...